348 related articles for article (PubMed ID: 25652012)
1. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.
Devulapally R; Sekar NM; Sekar TV; Foygel K; Massoud TF; Willmann JK; Paulmurugan R
ACS Nano; 2015 Mar; 9(3):2290-302. PubMed ID: 25652012
[TBL] [Abstract][Full Text] [Related]
2. Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy.
Ananta JS; Paulmurugan R; Massoud TF
Mol Pharm; 2016 Sep; 13(9):3164-75. PubMed ID: 27508339
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
4. Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy.
Ahir M; Upadhyay P; Ghosh A; Sarker S; Bhattacharya S; Gupta P; Ghosh S; Chattopadhyay S; Adhikary A
Biomater Sci; 2020 May; 8(10):2939-2954. PubMed ID: 32319481
[TBL] [Abstract][Full Text] [Related]
5. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
[TBL] [Abstract][Full Text] [Related]
6. Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.
Bhargava-Shah A; Foygel K; Devulapally R; Paulmurugan R
Nanomedicine (Lond); 2016 Feb; 11(3):235-47. PubMed ID: 26787319
[TBL] [Abstract][Full Text] [Related]
7. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
Miller-Kleinhenz JM; Bozeman EN; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
[TBL] [Abstract][Full Text] [Related]
8. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
Falkenberg N; Anastasov N; Schaub A; Radulovic V; Schmitt M; Magdolen V; Aubele M
Oncotarget; 2015 Apr; 6(10):8103-14. PubMed ID: 25797271
[TBL] [Abstract][Full Text] [Related]
9. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
10. "Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.
Su S; Tian Y; Li Y; Ding Y; Ji T; Wu M; Wu Y; Nie G
ACS Nano; 2015 Feb; 9(2):1367-78. PubMed ID: 25611071
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
12. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
[TBL] [Abstract][Full Text] [Related]
13. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
14. Preparation, characterization, and in vitro tumor-suppressive effect of anti-miR-21-equipped RNA nanoparticles.
Zhang T; Wu Y; Yang D; Wu C; Li H
Biochem Biophys Res Commun; 2021 Jun; 558():107-113. PubMed ID: 33906109
[TBL] [Abstract][Full Text] [Related]
15. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
16. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
Luo G; Yu X; Jin C; Yang F; Fu D; Long J; Xu J; Zhan C; Lu W
Int J Pharm; 2010 Jan; 385(1-2):150-6. PubMed ID: 19825404
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
Vangara KK; Liu JL; Palakurthi S
Anticancer Res; 2013 Jun; 33(6):2425-34. PubMed ID: 23749891
[TBL] [Abstract][Full Text] [Related]
18. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.
Zhou W; Song F; Wu Q; Liu R; Wang L; Liu C; Peng Y; Mao S; Feng J; Chen C
PLoS One; 2017; 12(4):e0176395. PubMed ID: 28437471
[TBL] [Abstract][Full Text] [Related]
19. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R
Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657
[TBL] [Abstract][Full Text] [Related]
20. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
